Compare MOBX & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | HSCS |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 15.8M |
| IPO Year | 2021 | 2022 |
| Metric | MOBX | HSCS |
|---|---|---|
| Price | $0.75 | $3.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 124.8K |
| Earning Date | 08-18-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,442,000.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 426.31 | N/A |
| 52 Week Low | $0.13 | $1.63 |
| 52 Week High | $4.25 | $5.25 |
| Indicator | MOBX | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 40.41 |
| Support Level | $0.71 | $1.84 |
| Resistance Level | $1.34 | $3.72 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 13.81 | 6.32 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.